Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-15. Numbers and descriptions here follow the published literature rather than marketing material.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Many gas chromatograph detectors are ion detectors with varying methods of ionizing the components eluting from the gas chromatograph's column. An ion detector is analogous to a capacitor or vacuum tube. It can be envisioned as two metal grids separated by air with inverse charges placed on them. An electric potential difference (voltage) exists between the two grids. After components are ionized in the detector, they enter the region between the two grids, causing current to pass from one to the other. This current is amplified and is the signal generated by the detector. The higher the concentration of the component, the more ions are generated, and the greater the current. Some early FIDs actually used two metal grids as their ion detectors. However, more efficient designs have been developed, so few current ion-type detectors use two metal grids. But the principle is the same, and it can be easiest to think of the detector in this manner.
The giant gourami is also popular in aquaria. Tanks commonly have dark bottoms, with densely planted edges, and room left in the center of the tank for them to swim. They prefer the company of other fish of similar sizes and temperament. They are easy to keep at three months old at around 7.5 cm (3 in long). At this age, they have a pronounced beak. They can grow rapidly given sufficient food and space to move. Even under less than ideal conditions, gourami can grow from 7.5 cm (3 in) to 50 cm (19 in) four years. At this age, in addition to the rounded face, a mature giant gourami will have begun to develop the hump just above its eyes. Taiwanese and Malaysians admired fish with protruding heads, known as 'kaloi' or 'warships', found in the western part of the nation. The slightly protruding forehead and long tail of these fish were prized in Taiwanese society as bringing luck in geomancy. A gourami in a community tank will snap and charge any other fish which are small enough for it to bully. Like most aquarium dwellers, giant gourami can be quickly raised with larger, more passive fish. However, if other fish are added to a tank, either large or small, they might be killed within a short period.
Some pregnant women and care providers choose to forgo routine screening due to the absence of risk factors; however, this is not advised due to the large proportion of women who develop gestational diabetes despite having no risk factors present and the dangers to the mother and baby if gestational diabetes remains untreated.
Other proteins bind to the ends of actin filaments, stabilizing them. These are called "capping proteins" and include CapZ and tropomodulin. CapZ binds the (+) end of a filament, preventing further addition or loss of actin from that end. Tropomodulin binds to a filament's (−) end, again preventing addition or loss of molecule's at that end. Tropomodulin is typically found in cells that require extremely stable actin filaments, such as those in muscle and red blood cells. These actin binding proteins are typically regulated by various cellular signals to control actin assembly dynamics in different cellular locations. Formins, for example, are typically folded in an inactive conformation until they're activated by the binding of the small GTPase Rho. Actin branching at the cell membrane is important for cell movement, and so the plasma membrane lipid PIP2 activates the nucleation promoting factor WASp and inhibits CapZ. WASp is also activated by the small GTPase Cdc42, while another nucleation promoting factor WAVE is activated by the GTPase Rac1.
In Latin America 62% of people believe that the level of corruption had risen in the last 12 months according to a study in 2017. People feel this way due to a number of ways in which governments use corruption to gain money and power at the expense of their people. In Venezuela the Maduro regime has been known to allow transnational criminal organizations. This is along with money laundering, or illicit finance, which keeps money in the pockets of criminals and government officials instead of the people.
Sources: en.wikipedia.org
In a study with 17 volunteers, blood and saliva samples were collected before and at 15, 30, 60 and 240 min after ingesting 1 g of paracetamol. Detection from stimulated saliva and plasma with PA-MS provided a reliable result that can aid in making timely treatment decisions. Moreover, participants' views of blood and saliva sampling procedures were assessed qualitatively, showing a preference for non-invasive sampling.
=== Other sequences === Chain bridge, type of suspension bridge Chain crew, crew that manages signal poles in gridiron football Chain gang, group of prisoners chained together as a form of punishment Chain letter, a message that attempts to induce the recipient to make a number of copies of the message and then pass them on to one or more new recipients Chain of events, a number of actions and their effects that are linked together Chain smoking, practice of smoking several cigarettes/cigars in succession Chain stitch, in sewing and embroidery, a series of looped stitches that form a chain Chaining, a technique from applied behavioral analysis for teaching complicated tasks by breaking them into simpler steps Hudson River Chains, one of several chains used in blockades of the Hudson River Human chain (politics), a form of protest Signifying chain, in semiotics, an interlocking system of signifiers
After these winds slow down, sub-tropical westerlies guide extratropical Western disturbances from the Mediterranean Region and the Middle East across northwestern India, bringing rain for winter crops and replenishing the glaciers in the Karakorams. By May, the sun bakes the Tibetan Plateau. Rising warm air generates a high-altitude anticyclone. This creates the Tropical Easterly Jet Stream over southern India, which draws moisture-laden southwesterly surface winds off the Indian Ocean. The Western Ghats intercept these winds, which release their moisture as orographic rain, leaving a large swath of peninsular India in the mountains' rain shadow. India’s interior plains rely on monsoon depressions for their rain. These low-pressure storm systems form over the Bay of Bengal and are steered clockwise and inland by the anticyclonic jet stream. They cause summer rainfall across India from June to September. However, rainfall fluctuates in cycles, alternating between active phases characterised by heavy rain and dry breaks.
=== Pharmacological === Certain drugs or exogenous chemical compounds are known to affect inflammation. Vitamin A deficiency, for example, causes an increase in inflammatory responses, and anti-inflammatory drugs work specifically by inhibiting the enzymes that produce inflammatory eicosanoids. Additionally, certain illicit drugs such as cocaine and ecstasy may exert some of their detrimental effects by activating transcription factors intimately involved with inflammation (e.g. NF-κB).
Sources: en.wikipedia.org
=== Other potential methods === Diverse techniques to identify PPIs have been emerging along with technology progression. These include co-immunoprecipitation, protein microarrays, analytical ultracentrifugation, light scattering, fluorescence spectroscopy, luminescence-based mammalian interactome mapping (LUMIER), resonance-energy transfer systems, mammalian protein–protein interaction trap, electro-switchable biosurfaces, protein–fragment complementation assay, as well as real-time label-free measurements by surface plasmon resonance, and calorimetry.
Adopted from analytical chemistry, the term top down in proteomics means the separation of intact proteoforms and their subsequent identification, and is agnostic as to how that is achieved. Currently, there are two analytical approaches that enable proteome assessments to different extents: Integrative or Integrated TDP (iTDP; current usually utilizing routine high resolution/sensitivity two-dimensional gel electrophoresis tightly coupled with liquid chromatography and tandem mass spectrometry (2DE/LC/MS/MS)) or mass spectrometry-intensive TDP (MSi-TDP); while these terms may not yet be widely used, it is important to differentiate between these approaches as they enable quite different depths and comprehensiveness of proteome analysis. Such clear distinction is critical in terms of the transparency, accuracy, and thoroughness of proteome research. As always, it is critical for every study to fully describe the methods used. Thus, although currently most often utilizing 2DE/LC/MS/MS, iTDP is a more general term for the integration of the best available approaches to enable truly comprehensive, deep proteome analyses at the critically necessary level of intact proteoforms.
== History == Sucrose esters were first mentioned in 1880 by Herzfeld who described the preparation of sucrose octaacetate. The substance is still in use today as a food additive. In 1921, Hess and Messner synthesized sucrose octapalmitate and sucrose octastearate. Both are sucrose fatty acid esters. Rosenthal, in 1924, synthesized highly substituted sucrose fatty acid esters using the classical condensation reaction between sucrose and the acid chloride of the drying oil fatty acid; pyridine was used as a solvent. Rheineck, Rabin, and Long followed the same procedure using alternative polyhydroxyl molecules such as mannitol. These condensation gave low yields, and the products, which were dark in color, needed extensive purification. Moreover, pyridine is a toxic solvent, so the synthesis was not commercially successful. In 1939, Cantor, who patented a production route of sucrose fatty acid esters from starch factory by-products, claimed that the products could be used as emulsifying agents or fats. The classical esterification was used with a mixture of pyridine and either chloroform or carbon tetrachloride as a solvent. Later, the concept of synthesizing sucrose esters from sucrose and fatty acids was patented in 1952. The new synthesis pathway, which involved transesterification of triglycerides and sucrose in the new solvent dimethylformamide, or DMF, was invented and seemed promising.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.